Cargando…

Antirheumatic effects of humanized anti-Fas monoclonal antibody in human rheumatoid arthritis/SCID mouse chimera

Detalles Bibliográficos
Autores principales:	Matsuno, H, Yudoh, K, Nishioka, K
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833920/ http://dx.doi.org/10.1186/ar930

Ejemplares similares

Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras
Publicado: (1994)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Anti-Fas IgM monoclonal antibody (anti-Fas mAb) effect on haemophilic arthropathy (HA) synoviocytes
por: Guiducci, Serena, et al.
Publicado: (2012)

Binding immunoglobulin protein resolves rheumatoid synovitis: a xenogeneic study using rheumatoid arthritis synovial membrane transplants in SCID mice
por: Yoshida, Kaoru, et al.
Publicado: (2011)

Human-derived IgG level as an indicator for EBV-associated lymphoma model in Hu-PBL/SCID chimeras
por: Tang, Yunlian, et al.
Publicado: (2011)

Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs
por: Sokka, Tuulikki, et al.
Publicado: (2008)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
por: Mikhaylenko, Dmitry S., et al.
Publicado: (2020)

Atherosclerotic Cardiovascular Disease in Rheumatoid Arthritis: Impact of Inflammation and Antirheumatic Treatment
por: Kerola, Anne Mirjam, et al.
Publicado: (2021)

Antirheumatic treatment is associated with reduced serum Syndecan-1 in Rheumatoid Arthritis
por: Deyab, Gia, et al.
Publicado: (2021)

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis
por: Lim, Sung Ho, et al.
Publicado: (2022)

Epitope Mapping of Neutralizing Monoclonal Antibodies to Human Interferon-γ Using Human-Bovine Interferon-γ Chimeras
por: Zuber, Bartek, et al.
Publicado: (2016)

Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis
por: Guski, Louise S., et al.
Publicado: (2023)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
por: Bliddal, Sofie, et al.
Publicado: (2017)

Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies
por: Fazeli, Mir Sohail, et al.
Publicado: (2021)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies
por: Senolt, Ladislav
Publicado: (2019)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis
por: Kim, Wan-Uk, et al.
Publicado: (2007)

Oxidative stress induces chondrocyte telomere instability and chondrocyte dysfunctions in osteoarthritis
por: Yudoh, K, et al.
Publicado: (2003)

Long-term human hematopoiesis in the SCID-hu mouse
Publicado: (1990)

Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
por: Joo, Young Bin, et al.
Publicado: (2022)

Evaluation of the anti-RANKL monoclonal antibody in rheumatoid arthritis rats
por: Lv, Dawei, et al.
Publicado: (2022)

Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments
por: Chi, Xiao-Kai, et al.
Publicado: (2023)

Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis
por: Jain, Vikramraj K., et al.
Publicado: (2017)

Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy
por: McKenzie, Callum, et al.
Publicado: (2023)

Preclinical screening for acute toxicity of therapeutic monoclonal antibodies in a hu-SCID model
por: Brady, Jamie L, et al.
Publicado: (2014)

The immunodeficient scid mouse as a model for human lymphatic filariasis
Publicado: (1991)

Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach
por: Matsuo, Kosuke, et al.
Publicado: (2006)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia
por: Fletcher, Ashley, et al.
Publicado: (2022)

The effect of disease-modifying antirheumatic drugs on sleep and quality of life in older patients with rheumatoid arthritis
por: Azizli, Ali, et al.
Publicado: (2023)

Comparative effectiveness of JAK inhibitors and biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2023)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis
por: Huang, Yinan, et al.
Publicado: (2023)

Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
por: Ally, Mahmood M. T. M., et al.
Publicado: (2015)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
por: Smolen, Josef S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v0u35ok75scqcecrda6ivvtefd